|
Treatment group
| |
Total
|
A1
|
A2
|
B1
|
B2
|
|---|
|
Patient number
| |
66
|
15
|
18
|
17
|
16
|
|
Age, years
|
Median
|
54
|
44
|
47
|
58
|
56
|
|
min.–max.
|
26–70
|
31–64
|
26–63
|
35–70
|
41–70
|
|
T
|
T1c
|
13
|
5
|
3
|
2
|
3
|
|
T2
|
48
|
9
|
13
|
14
|
12
|
|
T3
|
5
|
1
|
2
|
1
|
1
|
|
N
|
N0
|
39
|
7
|
11
|
11
|
10
|
|
N1
|
27
|
8
|
7
|
6
|
6
|
|
Histological grade (B and R)
|
1
|
2
|
1
|
0
|
0
|
1
|
|
2
|
17
|
2
|
4
|
5
|
6
|
|
3
|
44
|
11
|
14
|
11
|
8
|
|
Unknown
|
3
|
1
|
0
|
1
|
1
|
|
Ki67 labeling index, %
|
Median
|
57.7
|
55
|
64.2
|
51.6
|
50.4
|
|
min.–max.
|
16.2–90
|
20.2–90
|
36.4–89.6
|
20–89
|
16.2–82
|
|
HRD
|
Low
|
18
|
0
|
0
|
9
|
9
|
|
High
|
33
|
15
|
18
|
0
|
0
|
|
Unknown
|
15
|
0
|
0
|
8
|
7
|
|
tBRCA1/2 mutation
|
BRCA1 mutation
|
6
|
3
|
3
|
0
|
0
|
|
BRCA2 mutation
|
6
|
3
|
3
|
0
|
0
|
|
No mutation
|
43
|
9
|
12
|
12
|
10
|
|
Unknown
|
11
|
0
|
0
|
5
|
6
|
|
pCR
|
Yes
|
23
|
10
|
8
|
2
|
3
|
|
No
|
43
|
5
|
10
|
15
|
13
|
|
%
|
34.8
|
66.7
|
44.4
|
11.8
|
18.8
|
- A1 group taking paclitaxel + carboplatin, A2 group taking eribulin + carboplatin, B1 eribulin + cyclophosphamide, B2 eribulin + capecitabine, HRD homologous recombination deficiency, tBRCA tumor BRCA, max. maximum, min. minimum, pCR pathological complete response
